The past two-and-a-half years have been rough for Moderna (NASDAQ: MRNA). Though the biotech was highly successful in the COVID-19 vaccine market, investors rightly expecting this niche to shrink started selling off the stock in early 2022. The vaccine maker's shares are down by 43% since then. Moderna ...
motleyfoolusx:mrna
Shares of vaccine stocks Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), and BioNTech SE (NASDAQ: BNTX) rallied this week, appreciating 23.4%, 16.4%, and 9.3%, respectively, through Thursday trading, according to data from S&P Global Market Intelligence. While these three stocks gained notoriety back ...
motleyfoolusx:mrnausx:bntxusx:nvax
Moderna (NASDAQ: MRNA) isn't new to artificial intelligence (AI). The biotech best known for its billion-dollar coronavirus vaccine has been using this hot technology for years to help it save crucial time in the laboratory. For example, Moderna uses AI to produce mRNAs for researchers to work with, ...
motleyfoolusx:mrna
Equities have been on a bull run for well over a year. Though it might be tempting to invest in stocks that have largely been in tandem with the broader market, it's even better to consider those companies that have failed to keep pace, provided they display solid upside potential. Let's consider two ...
motleyfoolusx:mrnausx:dxcm
Moderna (NASDAQ: MRNA) and OpenAI are collaborating to bring artificial intelligence (AI) to every level of the biotech's operations, and the implications could perhaps be significant for investors. If the lofty claims made by others in the biotech industry are true, the company could see a smattering ...
motleyfoolusx:mrna
Five years ago, pharmaceutical company Moderna (NASDAQ: MRNA) was mostly unknown. It was developing vaccines that induce human immune cells to more effectively fight disease. But the science of DNA-based drugs was on the experimental fringe of the biopharma landscape. Not too many investors were looking ...
motleyfoolusx:mrna
Moderna (NASDAQ: MRNA) was a fine stock to heal an ailing portfolio on the second-to-last trading day of the week. The company, which developed and sells the Spikevax COVID-19 vaccine, saw its share price balloon by almost 13% thanks to an encouraging set of quarterly results. With that rise, it easily ...
motleyfoolusx:mrna
Image source: The Motley Fool. Moderna (NASDAQ: MRNA) Q1 2024 Earnings Call May 02, 2024, 8:00 a.m. ET Operator Continue reading
motleyfoolusx:mrna
Moderna, Inc. (NASDAQ: MRNA) reported a net loss for the first quarter of 2024 when the biotechnology company’s revenues declined sharply. Q1 loss was $1.18 billion or $3.07, compared to a profit of $79 million or $0.19 per share in the prior-year period. The bottom line was negatively impacted by a ...
alphastreetusx:mrna
The bull market is roaring higher, and many growth stocks have led the gains -- but this doesn't mean your opportunity to buy growth stocks for a good price is over. Plenty of players with great long-term prospects haven't yet benefited from this favorable market environment, and instead have remained ...
motleyfoolusx:mrnausx:ntla
According to some new data revealed by Moderna (NASDAQ: MRNA) at the American Association for Cancer Research Annual Meeting on April 8, the biotech responsible for the Spikevax coronavirus vaccine may have another blockbuster drug in the works, this time a personalized cancer vaccine (PCV) for head ...
motleyfoolusx:mrnausx:mrk
